Compare ENSC & ZCMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENSC | ZCMD |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | China |
| Employees | N/A | 33 |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 7.1M |
| IPO Year | 2017 | 2019 |
| Metric | ENSC | ZCMD |
|---|---|---|
| Price | $0.56 | $1.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 464.1K | 241.9K |
| Earning Date | 11-13-2026 | 12-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.24 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,066,650.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.02 |
| 52 Week High | $2.75 | $11.96 |
| Indicator | ENSC | ZCMD |
|---|---|---|
| Relative Strength Index (RSI) | 73.13 | 56.72 |
| Support Level | $0.47 | $1.25 |
| Resistance Level | $0.61 | $1.69 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 91.64 | 52.73 |
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.